Design of the Pravastatin or Atorvastation Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial

The Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) trial has 2 main objectives: (1) to compare pravastatin with atorvastatin with the goal of determining whether lowering low-density lipoprotein (LDL) cholesterol with pravastatin to a level of approximately 100 mg/dl provides a clinical benefit similar to LDL cholesterol lowering with atorvastatin to a much lower level of approximately 70 mg/dl; and (2) to examine the role of Chlymadia pneumoniae (C. pneumoniae) infection in cardiovascular disease by evaluating the effectiveness of the antibiotic gatifloxacin in reducing cardiovascular events.